ClinicalTrials.gg
RecruitingNCT05648214Updated Apr 16, 2026

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase 1/2 interventional study of ALN-PNP and Placebo (PB) in Healthy Volunteers and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), sponsored by Regeneron Pharmaceuticals. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
28th of 162
172 · median 45
Started
2022
with 9 others
Phase 1/2
12 of 211
3 open now
Primary completion
2027-08
later than 17 of 46 live
Registered
165th of 211
by date

Among the 211 studies in Fatty Liver with a site in United States, this one is the 28th largest by planned enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2022, is one of 12 in phase 1/2, reaches primary completion later than 17 of the 46 other live ones, and was the 165th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment.

This study consists of 3 parts. Part A is focused on healthy participants. Parts B and C of the study are focused on participants who are known to have MASLD and a specific variant of the PNPLA3 gene.

The aim of the study is to see how safe, tolerable and effective the study drug is.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug (Parts A, B and C)
  • How much study drug (Parts A, B and C) and study drug metabolites (byproduct of the body breaking down the study drug) (Parts B and C) are in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) (Part A, B and C)
  • Explore impact of Japanese ethnicity on safety and PK (Pharmacokinetics, or study of what the body does to the drug) of single doses of ALN-PNP over time (Part A)
  • How the study drug works to change liver fat content in MASLD (Part B and C)
  • Better understanding of the study drug and MASLD (Part B and C)
03

Conditions studied

  • Healthy Volunteers
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Keywords

  • Liver steatosis
  • Fibrosis
  • Hepatocytes
  • Non-Alcoholic Steatohepatitis (NASH)
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Metabolic dysfunction-Associated Steatohepatitis (MASH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part A (Healthy Adults):

  1. From 18 to 55 years of age
  2. For Japanese cohorts ONLY; the Japanese participant must:

    1. Be Japanese, born in Japan, and have both biologic parents and 4 biologic grandparents who are ethnically Japanese and born in Japan
    2. Have maintained a Japanese lifestyle, with no significant change since leaving Japan, including having access to Japanese food and adhering to a Japanese diet
    3. Be living \<10 years outside of Japan
  3. Has a (BMI) between 18 and 32 kg/m\^2, inclusive, at the screening visit
  4. Is judged by the investigator to be in good health, as described in the protocol
  5. Is in good health based on laboratory safety testing obtained at the screening visit and approximately within 24 hours prior to administration of study drug

Part B and Part C (Participants with MASLD):

  1. Part B: From 18 to 65 years of age
  2. Part C: From 18 to 75 years of age
  3. BMI from 23.0 kg/m2 to 40.0 kg/m2, inclusive, for East Asians (including but not limited to South Koreans, Chinese, Taiwanese, and Japanese) and BMI from 27.0 kg/m2 to 40.0 kg/m2, inclusive, for any other ethnicity at screening visit 1
  4. Liver fat content ≥8.5% as measured by MRI-PDFF at screening visit 3

Key Exclusion Criteria:

Part A:

  1. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, neurological, or dermatologic disease, as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation
  2. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
  3. Hospitalized for any reason within 30 days of the screening visit
  4. Using the Modification of Diet in Renal Disease equation, has a as described in the protocol at the screening visit
  5. Has (ALT) or Aspartate Aminotransferase (AST) or total above the (ULN) range
  6. Is a current smoker or former smoker, including e-cigarettes, who stopped smoking within 3 months prior to the screening visit
  7. Has a history of alcohol or drug abuse per investigator opinion
  8. Is positive for antibody and if so, positive for qualitative (ie, detected or not detected) Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) test at the screening visit

Part B and Part C:

  1. Evidence of other forms of known chronic liver disease, as defined in the protocol
  2. Has a to MRI examinations, as defined in the protocol
  3. History of Type 1 diabetes
  4. Has lost or gained more than 4.0% body weight over the 3 months prior to or during the screening period
  5. Has known (HIV) infection, evidence of current or chronic Virus (HBV) infection, or current or chronic HCV infection, as defined in the protocol
  6. Bariatric surgery within approximately 5 years (Part B) or 3 years (Part C) prior or planned during the study period

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Part A: Cohorts

    Drug: ALN-PNP · Drug: Placebo (PB)

  • Experimental
    Part A: Optional Cohort

    Drug: ALN-PNP · Drug: Placebo (PB)

  • Experimental
    Part A: JPN Cohorts

    Drug: ALN-PNP · Drug: Placebo (PB)

  • Experimental
    Part B: Cohorts

    Drug: ALN-PNP · Drug: Placebo (PB)

  • Experimental
    Part C: Cohorts

    Drug: ALN-PNP · Drug: Placebo (PB)

Interventions

  • DrugALN-PNP

    Administered per the protocol

  • DrugPlacebo (PB)

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 337

  2. Severity of TEAEs

    Time frame: Up to Day 337

Secondary outcomes

  1. Concentration of ALN-PNP and potential major metabolite(s) in plasma

    Time frame: Up to Day 337

  2. Incidence of Anti-Drug Antibodies (ADAs) to ALN-PNP

    Time frame: Up to Day 337

  3. Magnitude of ADAs to ALN-PNP

    Time frame: Up to Day 337

  4. Change in Low-Density Lipoprotein (LDL)

    Part A

    Time frame: Baseline up to Day 169

  5. Change in High-Density Lipoprotein (HDL)

    Part A

    Time frame: Baseline up to Day 169

  6. Change in TriGlyceride (TG)

    Time frame: Baseline up to Day 337

  7. Change in Apolipoprotein B (ApoB)

    Time frame: Baseline up to Day 337

  8. Change in liver fat fraction by Magnetic Resonance Imaging derived Proton-Density Fat Fraction (MRI-PDFF)

    Part B and Part C

    Time frame: Baseline up to Day 253

  9. Change in Low-Density Lipoprotein Cholesterol (LDL-C)

    Part B and Part C

    Time frame: Baseline up to Day 337

  10. Change in High-Density Lipoprotein Cholesterol (HDL-C)

    Part B and Part C

    Time frame: Baseline up to Day 337

  11. Change in Lipoprotein (a) (Lp[a])

    Part B and Part C

    Time frame: Baseline up to Day 337

  12. Change in Apolipoprotein A1 (ApoA1)

    Part B and Part C

    Time frame: Baseline up to Day 337

  13. Change in small dense Low-Density Lipoprotein (sdLDL)

    Part C

    Time frame: Baseline up to Day 337

07

Study locations

5 of 6 sites recruiting
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
    Completed

    Not enrolling at this site.

  • Velocity Clinical research
    Los Angeles, California 90057, United States
    Recruiting
  • Genoma Research Group, Inc
    Miami, Florida 33173, United States
    Recruiting
  • Med Research of Florida, LLC
    Miami, Florida 33186, United States
    Recruiting
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
    Recruiting
  • Pioneer Research Solutions
    Houston, Texas 77099, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Aug 2027, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Dec 27, 2022
Primary completionEst.
Aug 10, 2027
CompletionEst.
Aug 10, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648214
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Dec 27, 2022
Primary completion
Aug 10, 2027 (estimated)
Completion
Aug 10, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion